11th & 12th February 2026
Royal Lancaster Hotel
Lancaster Terrace, London
A leadership forum uniting up to 200 pioneers across cell and gene therapy, CMC, supply and manufacturing — those shaping the future of advanced therapy production through digitisation, automation and intelligent operations.
Chairman: Uwe Gottschalk
Operating Partner, Keensight Capital · Former CSO, Lonza
2026 CGTI and BILS discussions align with the AIO Agenda, where AI, machine learning, digitisation and operational intelligence converge with human insight to strengthen quality, supply and scalable delivery in advanced therapy manufacturing.
Because without connection, innovation stalls.
THE IMPERATIVE
Advanced therapies cannot scale in isolation.
Science needs systems. Data needs direction. Supply needs alignment.
The future of cell and gene therapy depends on more than innovation.
It requires integration - where clinical design, digital intelligence and operational precision converge.
CGTI exists to build the intelligent enterprise of advanced therapy
linking discovery, CMC and supply in one connected ecosystem.
It is not a conference, it is a catalyst for transformation.
The goal is to deliver scalable, sustainable and patient-centred therapies through intelligent systems and collaborative execution.
WHY IT MATTERS
Advanced therapy is no longer defined by discovery alone.
Its success depends on how effectively science connects to manufacturing, supply and patient access.
CGTI matters because precision and purpose must coexist.
It brings together leaders across research, CMC and digital operations
to turn scientific complexity into scalable design.
By integrating analytics, automation and supply resilience CGTI enables a new standard for reliability and speed in therapy development.
It shifts the conversation from what is possible to what is operational.
The goal is to create therapies that are not only groundbreaking but built to reach every patient who needs them.
The connection
CGTI 2026 and BILS 2026 share one intelligent foundation that now extends through AIO 2026 - the architecture connecting science, systems and supply.
Together they form the backbone of advanced therapy manufacturing -
where discovery, development and delivery operate as one continuous system.
Merging these disciplines removes silos and builds an enterprise that learns, adapts and scales.
It connects the precision of CMC with the power of digital supply and embeds resilience at every stage of therapy development.
The goal is to create a connected value chain where innovation moves with purpose and patients benefit from progress built on trust and intelligence.
PAST SPEAKERS
Paolo Martini
Chief Research & Development Officer at ReAlta Life Sciences former CSO at Moderna
Warner Biddle
CEO at Kyverna Therapeutics former interim CEO at Kite a Gilead Company
Gwendolyn Binder PhD
President, Science and Technology at Cabaletta Bio
Who its curated for
Audience
Chief Operating Officers - transformation, scale, operating model
Heads of Manufacturing, MSAT and CMC process design, tech transfer, validation
Leaders in Data, AI and Automation - digital twins, advanced analytics, manufacturing IT
Quality and Regulatory Executives - QA, QMS, GxP, regulatory strategy
Also Welcome
Chief Data and Technology Officer
Head of Manufacturing IT/OT VP Supply Chain and Logistics Head of Cold Chain and Distribution
VP Quality Assurance
VP Regulatory Affairs
Head of Compliance and Release
CDMO executives: EVP Operations
Head of Client Programs
Why it matters
Science moves faster than the systems built to sustain it.
Applied intelligence turns information into infrastructure and links algorithms to execution - AI, automation and digital twins as living systems that learn and improve.
For biopharma it enables real-time oversight, continuous validation and reliability across networks.
For CGT it bridges innovation and access at scale without losing purpose.
CGTI 2026 | AIO
The Four Pillars of Advanced Therapy Intelligence
1. Intelligence
From data to design.
From design to delivery.
Where AI, automation and process analytics drive precision across CMC, development and manufacturing.
Why it matters: In a time of disruption and transformation, intelligence is human advantage - enabling leaders to anticipate, adapt and evolve beyond uncertainty.
2. Integration
From silos to synergy.
Bridging science, systems and supply through connected digital frameworks that learn, adapt and scale.
Why it matters: As global dynamics shift - tariffs, job cuts, supply constraints - integration becomes survival. True progress depends on unified systems that strengthen collaboration, resilience and trust.
3. Infrastructure
Where quality, innovation and agility align.
A living operational backbone powered by digital twins, modular design and compliant automation - engineered for flexibility and scale.
Why it matters: Resilient infrastructure is more than machinery. It’s the mindset that transforms volatility into opportunity and complexity into control.
4. Impact
From precision to purpose.
Where advanced therapies reach patients faster and sustain progress through adaptability, intelligence and shared responsibility.
Why it matters: In a world defined by change, impact is measured not just in outcomes - but in evolution. The ability to respond, rebuild and reimagine defines the future of healthcare.
Building pathways from research to patient access
ADVISORY & KEYNOTES
For the patients, we must do better.
ADVISORY
“Our very survival depends on our ability to stay awake, to adjust to new ideas, to remain vigilant and to face the challenge of change.” – Martin Luther King ...
Exploring automation and digital transformation in manufacturing
CGTI LONDON 2026
SUMMIT INSIGHTS
200+
Up to 200 decision-makers in person. Previous attendee demographics include 50% EMEA, 30% America and 20% ROW
20%
20% best-of-breed vendors providing solutions to combat the manufacturing, scale-up & R&D hurdles of today's C>
06
Journey of CXO presentations. Six insightful, powerful and inspirational talks from CXOs in the industry
02
Exclusive in-person networking, over 2 days in Barcelona, on the 10th and 11th of September
7+
Pre-scheduled and pre-qualified one-to-one meetings with delegates who influence or make a decision
90%
Over 90% of our attendance provided positive feedback. Please click here to see what our delegation has to say
WHY ATTEND
Exploring opportunities for small-scale CDMOs
Insights into key pain points such as shortage of talent and rising costs of supply chain
A deep dive into emerging biopharma pipelines and innovative emerging technologies
New innovations and strategies driving costs down and improving the manufacturing process
The promises and challenges of new therapeutic modalities
Leveraging innovation to bridge the gap from Gene to GMP
Executive training for commercial innovation and how to make a profitable growth
Navigating pricing, market access and reimbursement framework
Regulatory updates and compliance
As the industry scales to meet global demand, leaders face mounting geopolitical pressures, supply chain volatility and regulatory complexity - all while driving scientific innovation and ensuring patient access.
This summit offers exclusive access to insights, strategies and connections that can’t be found anywhere else. It’s not just another conference - it’s where executives shape the future of cell and gene therapy.
ACTION
-
Scale CGT from portfolio to patient access
-
MSAT playbook for scale and comparability
-
Connected supply and site readiness
-
Digital and data for QA and RTRT
-
Evidence and access that work
-
AI from design to factory (CGTI × DDIF)
-
Data that travels (CGTI × DDIF)
OUTCOME
-
MSAT access and supply aligned for speed
-
Faster tech transfer right first time release
-
Chain of identity protected faster turnaround
-
Real time oversight right first time release
-
Improved literacy donor services measurable outcomes
-
Models to RTRT right first time batches
-
FAIR standards and lineage traceable decisions
IMPACT
-
Cycle time reduced
-
Faster tech transfer
-
Fewer chain errors
-
Fewer deviations faster release
-
Higher participation better outcomes
-
Shorter cycle time
-
Faster tech transfer
SPEAKERS 2025
Be in the room where leaders decide
CGTI 2026 is where rare disease and cell and gene therapy leaders drive progress. An invite-only summit featuring selective partner showcases and strategic discussions.
